Comparison of Medication Prescribing Before and After the COVID-19 Pandemic Among Nursing Home Residents in Ontario, Canada | Clinical Pharmacy and Pharmacology | JAMA Network Open | JAMA Network
[Skip to Navigation]
Sign In
Figure 1.  Observed Weekly Proportion of Residents Dispensed Antipsychotics, Trazodone, Benzodiazepines, and Antidepressants Compared With Projected Use
Observed Weekly Proportion of Residents Dispensed Antipsychotics, Trazodone, Benzodiazepines, and Antidepressants Compared With Projected Use

Data were plotted from March 2019 to September 2020 to provide greater resolution for trends during the pandemic period.

Figure 2.  Observed Weekly Proportion of Residents Dispensed Anticonvulsants and Opioids Compared With Projected Use
Observed Weekly Proportion of Residents Dispensed Anticonvulsants and Opioids Compared With Projected Use

Data were plotted from March 2019 to September 2020 to provide greater resolution for trends during the pandemic period.

Figure 3.  Observed Weekly Proportion of Residents Dispensed Antibiotics, Angiotensin Receptor Blockers (ARBs), and Angiotensin-Converting Enzyme (ACE) Inhibitors Compared With Projected Use
Observed Weekly Proportion of Residents Dispensed Antibiotics, Angiotensin Receptor Blockers (ARBs), and Angiotensin-Converting Enzyme (ACE) Inhibitors Compared With Projected Use

Data were plotted from March 2019 to September 2020 to provide greater resolution for trends during the pandemic period.

Table 1.  Yearly Baseline Characteristics of Ontario Nursing Home Residents During Study Perioda
Yearly Baseline Characteristics of Ontario Nursing Home Residents During Study Perioda
Table 2.  Autoregressive Integrated Moving Average Model Results Summarizing the Association of the COVID-19 Pandemic With Medication Prescribing in Ontario Nursing Homes
Autoregressive Integrated Moving Average Model Results Summarizing the Association of the COVID-19 Pandemic With Medication Prescribing in Ontario Nursing Homes
1.
Le Couteur  DG, Anderson  RM, Newman  AB.  COVID-19 through the lens of gerontology.   J Gerontol A Biol Sci Med Sci. 2020;75(9):e119-e120. doi:10.1093/gerona/glaa077 PubMedGoogle ScholarCrossref
2.
Montero-Odasso  M, Hogan  DB, Lam  R,  et al.  Age alone is not adequate to determine health-care resource allocation during the COVID-19 pandemic.   Can Geriatr J. 2020;23(1):152-154. doi:10.5770/cgj.23.452 PubMedGoogle ScholarCrossref
3.
White  EM, Santostefano  CM, Feifer  RA,  et al.  Asymptomatic and presymptomatic severe acute respiratory syndrome coronavirus 2 infection rates in a multistate sample of skilled nursing facilities.   JAMA Intern Med. 2020;180(12):1709-1711. doi:10.1001/jamainternmed.2020.5664 PubMedGoogle ScholarCrossref
4.
Arons  MM, Hatfield  KM, Reddy  SC,  et al; Public Health–Seattle and King County and CDC COVID-19 Investigation Team.  Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility.   N Engl J Med. 2020;382(22):2081-2090. doi:10.1056/NEJMoa2008457 PubMedGoogle ScholarCrossref
5.
Richardson  S, Hirsch  JS, Narasimhan  M,  et al; the Northwell COVID-19 Research Consortium.  Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area.   JAMA. 2020;323(20):2052-2059. doi:10.1001/jama.2020.6775 PubMedGoogle ScholarCrossref
6.
Myers  LC, Parodi  SM, Escobar  GJ, Liu  VX.  Characteristics of hospitalized adults with COVID-19 in an integrated health care system in California.   JAMA. 2020;323(21):2195-2198. doi:10.1001/jama.2020.7202 PubMedGoogle ScholarCrossref
7.
Comas-Herrera  A, Zalakaín  J, Lemmon  E,  et al. Mortality associated with COVID-19 in care homes: international evidence. Updated February 1, 2021. Accessed May 4, 2020. https://ltccovid.org/2020/04/12/mortality-associated-with-covid-19-outbreaks-in-care-homes-early-international-evidence/
8.
McMichael  TM, Currie  DW, Clark  S,  et al; Public Health–Seattle and King County, EvergreenHealth, and CDC COVID-19 Investigation Team.  Epidemiology of COVID-19 in a long-term care facility in King County, Washington.   N Engl J Med. 2020;382(21):2005-2011. doi:10.1056/NEJMoa2005412 PubMedGoogle ScholarCrossref
9.
Barnett  ML, Grabowski  DC.  Nursing homes are ground zero for COVID-19 pandemic.   JAMA Health Forum. 2020;1(3):e200369. doi:10.1001/jamahealthforum.2020.0369 Google Scholar
10.
Ouslander  JG, Grabowski  DC.  COVID-19 in nursing homes: calming the perfect storm.   J Am Geriatr Soc. 2020;68(10):2153-2162. doi:10.1111/jgs.16784 PubMedGoogle ScholarCrossref
11.
Van Houtven  CH, DePasquale  N, Coe  NB.  Essential long-term care workers commonly hold second jobs and double- or triple-duty caregiving roles.   J Am Geriatr Soc. 2020;68(8):1657-1660. doi:10.1111/jgs.16509 PubMedGoogle ScholarCrossref
12.
McGregor  MJ, Harrington  C.  COVID-19 and long-term care facilities: does ownership matter?   CMAJ. 2020;192(33):E961-E962. doi:10.1503/cmaj.201714 PubMedGoogle ScholarCrossref
13.
Xu  H, Intrator  O, Bowblis  JR.  Shortages of staff in nursing homes during the COVID-19 pandemic: what are the driving factors?   J Am Med Dir Assoc. 2020;21(10):1371-1377. doi:10.1016/j.jamda.2020.08.002 PubMedGoogle ScholarCrossref
14.
McGarry  BE, Grabowski  DC, Barnett  ML.  Severe staffing and personal protective equipment shortages faced by nursing homes during the COVID-19 pandemic.   Health Aff (Millwood). 2020;39(10):1812-1821. doi:10.1377/hlthaff.2020.01269 PubMedGoogle ScholarCrossref
15.
Verbeek  H, Gerritsen  DL, Backhaus  R, de Boer  BS, Koopmans  RTCM, Hamers  JPH.  Allowing visitors back in the nursing home during the COVID-19 crisis: a Dutch national study into first experiences and impact on well-being.   J Am Med Dir Assoc. 2020;21(7):900-904. doi:10.1016/j.jamda.2020.06.020 PubMedGoogle ScholarCrossref
16.
Ailabouni  NJ, Hilmer  SN, Kalisch  L, Braund  R, Reeve  E.  COVID-19 pandemic: considerations for safe medication use in older adults with multimorbidity and polypharmacy.   J Gerontol A Biol Sci Med Sci. 2021;76(6):1068-1073. doi:10.1093/gerona/glaa104 PubMedGoogle ScholarCrossref
17.
Howard  R, Burns  A, Schneider  L.  Antipsychotic prescribing to people with dementia during COVID-19.   Lancet Neurol. 2020;19(11):892. doi:10.1016/S1474-4422(20)30370-7 PubMedGoogle ScholarCrossref
18.
Leontjevas  R, Knippenberg  IAH, Smalbrugge  M,  et al.  Challenging behavior of nursing home residents during COVID-19 measures in the Netherlands.   Aging Ment Health. 2020;1-6. PubMedGoogle Scholar
19.
Stall  NM, Zipursky  JS, Rangrej  J,  et al.  Assessment of psychotropic drug prescribing among nursing home residents in Ontario, Canada, during the COVID-19 pandemic.   JAMA Intern Med. 2021;181(6):861-863. doi:10.1001/jamainternmed.2021.0224 PubMedGoogle ScholarCrossref
20.
Canadian Institute for Health Information [CIHI]. Drug use among seniors in Canada, 2016. Canadian Institute for Health Information; 2018. Accessed December 16, 2020. https://www.cihi.ca/sites/default/files/document/drug-use-among-seniors-2016-en-web.pdf
21.
Maclagan  LC, Maxwell  CJ, Gandhi  S,  et al.  Frailty and potentially inappropriate medication use at nursing home transition.   J Am Geriatr Soc. 2017;65(10):2205-2212. doi:10.1111/jgs.15016 PubMedGoogle ScholarCrossref
22.
Iaboni  A, Bronskill  SE, Reynolds  KB,  et al.  Changing pattern of sedative use in older adults: a population-based cohort study.   Drugs Aging. 2016;33(7):523-533. doi:10.1007/s40266-016-0380-3 PubMedGoogle ScholarCrossref
23.
Iaboni  A, Campitelli  MA, Bronskill  SE,  et al.  Time trends in opioid prescribing among Ontario long-term care residents: a repeated cross-sectional study.   CMAJ Open. 2019;7(3):E582-E589. doi:10.9778/cmajo.20190052 PubMedGoogle ScholarCrossref
24.
Daneman  N, Campitelli  MA, Giannakeas  V,  et al.  Influences on the start, selection and duration of treatment with antibiotics in long-term care facilities.   CMAJ. 2017;189(25):E851-E860. doi:10.1503/cmaj.161437 PubMedGoogle ScholarCrossref
25.
Maust  DT, Kim  HM, Chiang  C, Kales  HC.  Association of the Centers for Medicare & Medicaid Services’ national partnership to improve dementia care with the use of antipsychotics and other psychotropics in long-term care in the United States from 2009 to 2014.   JAMA Intern Med. 2018;178(5):640-647. doi:10.1001/jamainternmed.2018.0379 PubMedGoogle ScholarCrossref
26.
Zhao  D, Shridharmurthy  D, Alcusky  MJ,  et al.  The prevalence and factors associated with antiepileptic drug use in US nursing home residents.   Drugs Aging. 2020;37(2):137-145. doi:10.1007/s40266-019-00732-2 PubMedGoogle ScholarCrossref
27.
Cohen  JB, D’Agostino McGowan  L, Jensen  ET, Rigdon  J, South  AM.  Evaluating sources of bias in observational studies of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use during COVID-19: beyond confounding.   J Hypertens. 2021;39(4):795-805. doi:10.1097/HJH.0000000000002706PubMedGoogle ScholarCrossref
28.
Danser  AHJ, Epstein  M, Batlle  D.  Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers.   Hypertension. 2020;75(6):1382-1385. doi:10.1161/HYPERTENSIONAHA.120.15082 PubMedGoogle ScholarCrossref
29.
Vaduganathan  M, Vardeny  O, Michel  T, McMurray  JJV, Pfeffer  MA, Solomon  SD.  Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19.   N Engl J Med. 2020;382(17):1653-1659. doi:10.1056/NEJMsr2005760 PubMedGoogle ScholarCrossref
30.
Quinn  KL, Fralick  M, Zipursky  JS, Stall  NM.  Renin-angiotensin-aldosterone system inhibitors and COVID-19.   CMAJ. 2020;192(20):E553-E554. doi:10.1503/cmaj.200619 PubMedGoogle ScholarCrossref
31.
Hippisley-Cox  J, Young  D, Coupland  C,  et al.  Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people.   Heart. 2020;106(19):1503-1511. doi:10.1136/heartjnl-2020-317393 PubMedGoogle ScholarCrossref
32.
Fosbøl  EL, Butt  JH, Østergaard  L,  et al.  Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality.   JAMA. 2020;324(2):168-177. doi:10.1001/jama.2020.11301 PubMedGoogle ScholarCrossref
33.
Reynolds  HR, Adhikari  S, Pulgarin  C,  et al.  Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19.   N Engl J Med. 2020;382(25):2441-2448. doi:10.1056/NEJMoa2008975 PubMedGoogle ScholarCrossref
34.
World Health Organization. COVID-19 and the use of angiotensin-converting enzyme inhibitors and receptor blockers. May 7, 2020. Accessed December 22, 2020. https://www.who.int/news-room/commentaries/detail/covid-19-and-the-use-of-angiotensin-converting-enzyme-inhibitors-and-receptor-blockers
35.
Vaduganathan  M, van Meijgaard  J, Mehra  MR, Joseph  J, O’Donnell  CJ, Warraich  HJ.  Prescription fill patterns for commonly used drugs during the COVID-19 pandemic in the United States.   JAMA. 2020;323(24):2524-2526. doi:10.1001/jama.2020.9184 PubMedGoogle ScholarCrossref
36.
Government of Ontario. Personal Health Information Protection Act, 2004, S.O. 2004, Chapter. 3, Schedule. A. Updated June 3, 2021. Accessed June 25, 2021. https://www.ontario.ca/laws/statute/04p03
37.
Langan  SM, Schmidt  SA, Wing  K,  et al.  The Reporting of Studies Conducted Using Observational Routinely Collected Health Data Statement for Pharmacoepidemiology (RECORD-PE).   BMJ. 2018;363:k3532. doi:10.1136/bmj.k3532 PubMedGoogle Scholar
38.
Ng  R, Lane  N, Tanuseputro  P,  et al.  Increasing complexity of new nursing home residents in Ontario, Canada: a serial cross-sectional study.   J Am Geriatr Soc. 2020;68(6):1293-1300. doi:10.1111/jgs.16394 PubMedGoogle ScholarCrossref
39.
Campitelli  MA, Bronskill  SE, Hogan  DB,  et al.  The prevalence and health consequences of frailty in a population-based older home care cohort: a comparison of different measures.   BMC Geriatr. 2016;16:133. doi:10.1186/s12877-016-0309-z PubMedGoogle ScholarCrossref
40.
Austin  PC.  Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.   Stat Med. 2009;28(25):3083-3107. doi:10.1002/sim.3697 PubMedGoogle ScholarCrossref
41.
Bernal  JL, Cummins  S, Gasparrini  A.  Interrupted time series regression for the evaluation of public health interventions: a tutorial.   Int J Epidemiol. 2017;46(1):348-355.PubMedGoogle Scholar
42.
Public Health Ontario. Daily epidemiologic summary: COVID-19 in Ontario: January 15, 2020 to December 21, 2020. 2020. Accessed January 8, 2021. https://files.ontario.ca/moh-covid-19-report-en-2020-12-22.pdf
43.
Helfenstein  U.  The use of transfer function models, intervention analysis and related time series methods in epidemiology.   Int J Epidemiol. 1991;20(3):808-815. doi:10.1093/ije/20.3.808 PubMedGoogle ScholarCrossref
44.
Dickey  DA, Fuller  WA.  Distribution of the estimators for autoregressive time series with a unit root.   J Am Stat Assoc. 1979;74(366):427-431. doi:10.2307/2286348Google ScholarCrossref
45.
Abbasi  J.  Social isolation—the other COVID-19 threat in nursing homes.   JAMA. 2020;324(7):619-620. doi:10.1001/jama.2020.13484 PubMedGoogle ScholarCrossref
46.
Ontario Drug Policy Research Network. COVID-19 Ontario prescription drug utilization tool. Updated June 16, 2021. Accessed December 22, 2020. https://odprn.ca/covid19-ontario-prescription-drug-utilization-tool/
47.
Macri  JC, Iaboni  A, Kirkham  JG,  et al.  Association between antidepressants and fall-related injuries among long-term care residents.   Am J Geriatr Psychiatry. 2017;25(12):1326-1336. doi:10.1016/j.jagp.2017.08.014 PubMedGoogle ScholarCrossref
48.
Watt  JA, Gomes  T, Bronskill  SE,  et al.  Comparative risk of harm associated with trazodone or atypical antipsychotic use in older adults with dementia: a retrospective cohort study.   CMAJ. 2018;190(47):E1376-E1383. doi:10.1503/cmaj.180551 PubMedGoogle ScholarCrossref
49.
Bronskill  SE, Campitelli  MA, Iaboni  A,  et al.  Low-dose trazodone, benzodiazepines, and fall-related injuries in nursing homes: a matched-cohort study.   J Am Geriatr Soc. 2018;66(10):1963-1971. doi:10.1111/jgs.15519 PubMedGoogle ScholarCrossref
50.
Hsu  J.  How COVID-19 is accelerating the threat of antimicrobial resistance.   BMJ. 2020;369:m1983. doi:10.1136/bmj.m1983 PubMedGoogle Scholar
51.
Strathdee  SA, Davies  SC, Marcelin  JR.  Confronting antimicrobial resistance beyond the COVID-19 pandemic and the 2020 US election.   Lancet. 2020;396(10257):1050-1053. doi:10.1016/S0140-6736(20)32063-8 PubMedGoogle ScholarCrossref
52.
Arshad  M, Mahmood  SF, Khan  M, Hasan  R.  COVID-19, misinformation, and antimicrobial resistance.   BMJ. 2020;371:m4501. doi:10.1136/bmj.m4501 PubMedGoogle Scholar
53.
Langford  BJ, So  M, Raybardhan  S,  et al.  Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis.   Clin Microbiol Infect. 2020;26(12):1622-1629. doi:10.1016/j.cmi.2020.07.016 PubMedGoogle ScholarCrossref
54.
Armitage  R, Nellums  LB.  Antibiotic prescribing in general practice during COVID-19.   Lancet Infect Dis. 2021;21(6):e144. doi:10.1016/S1473-3099(20)30917-8PubMedGoogle Scholar
55.
Daneman  N, Bronskill  SE, Gruneir  A,  et al.  Variability in antibiotic use across nursing homes and the risk of antibiotic-related adverse outcomes for individual residents.   JAMA Intern Med. 2015;175(8):1331-1339. doi:10.1001/jamainternmed.2015.2770 PubMedGoogle ScholarCrossref
56.
Taipale  H, Särkilä  H, Tanskanen  A,  et al.  Incidence of and characteristics associated with long-term benzodiazepine use in Finland.   JAMA Netw Open. 2020;3(10):e2019029. doi:10.1001/jamanetworkopen.2020.19029 PubMedGoogle Scholar
57.
Lornstad  MT, Aarøen  M, Bergh  S, Benth  JS, Helvik  AS.  Prevalence and persistent use of psychotropic drugs in older adults receiving domiciliary care at baseline.   BMC Geriatr. 2019;19(1):119. doi:10.1186/s12877-019-1126-y PubMedGoogle ScholarCrossref
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    Original Investigation
    Geriatrics
    August 2, 2021

    Comparison of Medication Prescribing Before and After the COVID-19 Pandemic Among Nursing Home Residents in Ontario, Canada

    Author Affiliations
    • 1ICES (formerly Institute for Clinical Evaluative Sciences), Toronto, Ontario, Canada
    • 2Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
    • 3Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    • 4Women’s College Research Institute, Women’s College Hospital, Toronto, Ontario, Canada
    • 5Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
    • 6Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, Ontario, Canada
    • 7Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
    • 8Department of Family Medicine, University of Alberta, Edmonton, Canada
    • 9Division of Geriatric Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
    • 10School of Pharmacy, University of Waterloo, Waterloo, Ontario, Canada
    • 11Public Health Sciences, University of Waterloo, Waterloo, Ontario, Canada
    JAMA Netw Open. 2021;4(8):e2118441. doi:10.1001/jamanetworkopen.2021.18441
    Key Points

    Question  How are COVID-19 and related disruptions in care associated with changes in the dispensation of medications commonly used among nursing home residents?

    Findings  In this population-based cohort study with an interrupted time-series analysis of all nursing home residents from the 630 facilities in Ontario, Canada, the emergence of the COVID-19 pandemic was associated with significant increases in the use of antipsychotics, benzodiazepines, antidepressants, anticonvulsants, and opioids and no meaningful changes in the use of antibiotics or selected cardiovascular medications.

    Meaning  The finding of increased use of medications with the potential for adverse effects among nursing home residents during the initial wave of the pandemic warrants ongoing monitoring for prescribing appropriateness and related resident outcomes.

    Abstract

    Importance  COVID-19 has had devastating effects on the health and well-being of older adult residents and health care professionals in nursing homes. Uncertainty about the associated consequences of these adverse effects on the use of medications common to this care setting remains.

    Objective  To examine the association between the COVID-19 pandemic and prescription medication changes among nursing home residents.

    Design, Setting, and Participants  This population-based cohort study with an interrupted time-series analysis used linked health administrative data bases for residents of all nursing homes (N = 630) in Ontario, Canada. During the observation period, residents were divided into consecutive weekly cohorts. The first observation week was March 5 to 11, 2017; the last observation week was September 20 to 26, 2020.

    Exposures  Onset of the COVID-19 pandemic on March 1, 2020.

    Main Outcomes and Measures  Weekly proportion of residents dispensed antipsychotics, benzodiazepines, antidepressants, anticonvulsants, opioids, antibiotics, angiotensin receptor blockers (ARBs), and angiotensin-converting enzyme (ACE) inhibitors. Autoregressive integrated moving average models with step and ramp intervention functions tested for level and slope changes in weekly medication use after the onset of the pandemic and were fit on prepandemic data for projected trends.

    Results  Across study years, the annual cohort size ranged from 75 850 to 76 549 residents (mean [SD] age, 83.4 [10.8] years; mean proportion of women, 68.9%). A significant increased slope change in the weekly proportion of residents who were dispensed antipsychotics (parameter estimate [β] = 0.051; standard error [SE] = 0.010; P < .001), benzodiazepines (β = 0.026; SE = 0.003; P < .001), antidepressants (β = 0.046; SE = 0.013; P < .001), trazodone hydrochloride (β = 0.033; SE = 0.010; P < .001), anticonvulsants (β = 0.014; SE = 0.006; P = .03), and opioids (β = 0.038; SE = 0.007; P < .001) was observed. The absolute difference in observed vs estimated use in the last week of the pandemic period ranged from 0.48% (for anticonvulsants) to 1.52% (for antipsychotics). No significant level or slope changes were found for antibiotics, ARBs, or ACE inhibitors.

    Conclusions and Relevance  In this population-based cohort study, statistically significant increases in the use of antipsychotics, benzodiazepines, antidepressants, anticonvulsants, and opioids followed the onset of the COVID-19 pandemic, although absolute differences were small. There were no significant changes for antibiotics, ARBs, or ACE inhibitors. Studies are needed to monitor whether changes in pharmacotherapy persist, regress, or accelerate during the course of the pandemic and how these changes affect resident-level outcomes.

    Introduction

    The COVID-19 pandemic has had a devastating effect on the quality of care and lives of at-risk older adults.1,2 Persons of advanced age with complex chronic conditions, many of whom reside in nursing homes, have high rates of infection3,4 and adverse health-related outcomes with COVID-19.5,6 In economically advantaged countries, 50% to 80% of COVID-19–related early deaths occurred among older adults in congregate care settings such as nursing homes.7 There was widespread transmission of SARS-CoV-2 in these settings, partially owing to structural and operating factors.8-12 Resulting workforce shortages and visitor restrictions led to both inadequate staffing13,14 and the barring of essential support by family and friends from these homes.15 The decline in available clinicians and other health care professionals, along with resident isolation and disruptions in communication, activities, and services during the pandemic, may have resulted in less timely and/or less appropriate clinical care and oversight, including in the management of medications.16

    A particular concern is that these challenges may have led to a rise in the overuse, misuse, and/or underuse of medications commonly targeted by quality improvement initiatives in the nursing home setting. Although data remain scarce, worries remain about the potential for increased use of psychotropic medications (eg, antipsychotics, benzodiazepines, and antidepressants) among residents during the pandemic, possibly in response to an increase in depression, anxiety, and responsive behaviors coupled with less access to nonpharmacological interventions.17-19 Using Ontario databases, Stall et al19 reported small absolute increases (1.0% to 1.6%) in the mean monthly proportion of nursing home residents dispensed antipsychotics and antidepressants (including trazodone hydrochloride) during the period from March 1 to September 30, 2020, relative to January 1 to February 29, 2020. Beyond psychotropics,19-22 other therapies of interest that have yet to be investigated in this population include opioids, anticonvulsants, and antibiotics.20,23-26 In addition, the initial widespread media reports about the potential risks of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) in relation to COVID-19 may have temporarily altered prescribing patterns for these agents among older residents27-30 despite subsequent evidence against these early claims.31-34 A recent US study35 reported an initial peak in prescription dispensations from March 15 to 21, 2020, followed by a drop for several medications (including antibiotics), although dispensations declined less and remained more stable for ACE inhibitors and ARBs.

    As many jurisdictions look to reform nursing home care after the COVID-19 pandemic, it is important to understand whether and to what extent the pandemic affected medication prescribing for older, frail adults in this setting. Our objective was to comprehensively examine the association between the initial wave of the COVID-19 pandemic and changes in medication dispensation patterns among nursing home residents. We focused on psychotropics, anticonvulsants, opioids, and antibiotics (ie, medication classes potentially subject to inappropriate use in nursing homes) as well as ARBs and ACE inhibitors, the latter in view of possible declines in their use after earlier controversial media reports.

    Methods
    Study Design and Setting

    We conducted a population-based cohort study with interrupted time-series analysis of medication use among nursing home residents in Ontario, Canada, from March 5, 2017, to September 26, 2020, using health administrative databases. These databases have been used extensively in previous research21-24 and were linked using unique encoded identifiers and analyzed at ICES (formerly the Institute for Clinical Evaluative Sciences). ICES is an independent, not-for-profit research institute whose legal status under Ontario’s health information privacy law allows it to collect and analyze health care and demographic data, without consent, for health system evaluation and improvement. Our study was authorized under section 45 of Ontario’s Personal Health Information Protection Act,36 which does not require review by a research ethics board. Six hundred thirty nursing homes operated in the province during the study period. These facilities provide 24-hour access to nursing and personal care. The Ontario publicly funded provincial health plan covers most nursing home costs and provides residents with universal access to physician services and prescription medications included on the provincial drug program formulary. This study is reported per the Reporting of Studies Conducted Using Observational Routinely Collected Health Data for Pharmacoepidemiology (RECORD-PE) guidelines.37

    We divided our study period into 186 observation weeks, which started on a Sunday (index date) and ended on a Saturday (first week, March 5-11, 2017; last week, September 20-26, 2020). For each week, we created a cohort of individuals residing in an Ontario nursing home who were alive and eligible to receive medication on the index date. Residence in a nursing home was determined using an algorithm38 based on medication claims from the Ontario Drug Benefit database and physician visits from the Ontario Health Insurance Plan database. Specifically, individuals were identified as living in a nursing home on the index date if, in the 90 days before the index date, they had at least 2 Ontario Drug Benefit claims dispensed to a nursing home (separated by ≥7 days) and/or at least 1 physician billing claim to the nursing home setting (eFigure 1 in the Supplement).

    On each weekly index date, we excluded residents concurrently admitted to an inpatient facility (0.3%-1.2% of residents across study weeks), without a previous full Resident Assessment Instrument Minimum Data Set, version 2.0, in the Continuing Care Reporting System database (2.7%-3.6% of residents across study weeks), with missing age and/or sex, or 110 years or older (<0.01% of residents across study weeks).

    Data Sources and Measures

    Details of the health administrative databases used in this study are provided in eTable 1 in the Supplement. At the index date for each weekly cohort, age, sex, and date of death were obtained from the Ontario Registered Persons database. The Canadian Institute for Health Information (CIHI) Discharge Abstract Database was used to capture concurrent inpatient admissions for residents. In addition, data collected from the most recent full Resident Assessment Instrument Minimum Data Set administration before the index date were used to compute a validated measure of frailty21,39 and identify the presence of common comorbidities, including dementia.

    We examined various central nervous system medication classes (antipsychotics, benzodiazepines, antidepressants [including trazodone, given its increasing use in nursing homes],22 anticonvulsants, and opioids), antibiotics, ARBs, and ACE inhibitors (eTable 2 in the Supplement). For residents in each weekly cohort, we used the Ontario Drug Benefit database to identify those receiving a medication of interest within the observation week based on the dispensation date and days of medication supplied (eFigure 1 in the Supplement).

    Statistical Analysis

    Standardized differences were used to compare resident characteristics between the first weekly cohort in March 2020 and each of the first weekly cohorts in March 2017, 2018, and 2019, with a threshold of greater than 10% representing a clinically meaningful difference.40 Each medication or class was analyzed separately. We computed the weekly number of individuals dispensed a medication per 100 nursing home residents. Interventional autoregressive integrated moving average (ARIMA) models were used to examine the association of the pandemic with medication use. These models allowed examination of changes in medication prescribing while accounting for serial correlation between consecutive weekly observations (ie, autocorrelation).41 Observation weeks from March 1, 2020, and onward were defined as the pandemic period (n = 30); earlier weeks were defined as the prepandemic period (n = 156). We selected March 1, 2020, because COVID-19 cases were evident (or suspected) in Ontario nursing home sites during early March,42 and the emergence of these cases would have been expected to gradually limit staffing, family support, and care. To test for both an immediate change in level of prescribing and a slope change in weekly medication use after the onset of the pandemic period, our models included a step intervention function and a ramp intervention function, respectively.43 Differencing our weekly data by a lag of 1 week accounted for longitudinal time trends in medication use across the study period and created a stationary series; stationarity was confirmed using augmented Dickey-Fuller tests.44 Plots of the autocorrelation function and partial autocorrelation function by weekly lags were used to guide the selection of autoregressive and moving average terms into the ARIMA model; these plots suggested a term was needed to account for an annual trend (52 weeks) when analyzing opioid and antibiotic dispensations (model details are provided in eTable 3 in the Supplement). We examined model fit using autocorrelation function and partial autocorrelation function plots of the model residuals, normality plots of the model residuals, Ljung-Box χ2 tests for white noise, and model forecast estimates.

    For each medication or class of interest, ARIMA models were also fit to the weeks from the prepandemic period only to forecast the projected weekly proportion of use during observation weeks in the pandemic period. In doing so, we could compare observed weekly medication use during the COVID-19 pandemic with the projected use in the hypothetical absence of a pandemic.

    Because psychotropic medications are commonly used and pose specific risks for older residents with dementia,17,25 we repeated the ARIMA model analysis among residents with dementia in sensitivity analyses (model details are provided in eTable 4 in the Supplement). Analyses were conducted using SAS, version 9.4 (SAS Institute, Inc). and all statistical tests used 2-sided P < .05 as the threshold for significance.

    Results

    Across study years, the annual cohort size ranged from 75 850 to 76 549 residents (mean [SD] age, 83.4 [10.8] years; mean proportion of women, 68.9%; mean proportion of men, 31.1%) (Table 1). The distribution of age, sex, frailty, and common comorbidities was similar (standardized differences, <10%) for the first weekly cohort in March 2020 compared with the first weekly cohorts in March 2017, 2018, and 2019. A plot of the weekly number of residents across the study period is presented in eFigure 2 in the Supplement.

    The overall trends in weekly medication use over time (all classes) are shown in eFigure 3 in the Supplement. Antidepressants (exclusive of trazodone) were the most commonly dispensed medications (52.5% [36 288/69 089 residents in the last study week]), followed by antipsychotics (26.9% [18 563/69 089 residents in the last study week]) and trazodone (26.2% [18 125/69 089 residents in the last study week]). Figure 1, Figure 2, and Figure 3 illustrate trends observed for each medication or class separately (To clearly illustrate observed vs projected estimates after pandemic onset, it was necessary to vary the y-axis). We observed a significant, increased slope change (ramp intervention) among weekly antipsychotic (parameter estimate [β] = 0.051; standard error [SE] = 0.010; P < .001), antidepressant (β = 0.046; SE = 0.013; P < .001), trazodone (β = 0.033; SE = 0.010; P < .001), and anticonvulsant (β = 0.014; SE = 0.006; P = .03) use after the onset of the pandemic period (Table 2). There was also a significant, increased slope change among weekly benzodiazepine (β = 0.026; SE = 0.003; P < .001) and opioid (β = 0.038; SE = 0.007; P < .001) use after the onset of the pandemic, which represented a reversal from the decreasing trends noted for both classes in the prepandemic period. The absolute difference in observed vs projected use in the last week of the pandemic period was highest for antipsychotics (1.52%), followed by antidepressants (1.43%), trazodone (1.06%), opioids (1.06%), benzodiazepines (0.64%), and anticonvulsants (0.48%).

    Both the step and ramp interventions were not statistically significant when analyzing changes in the weekly proportion of antibiotic, ARB, and ACE inhibitor use after the onset of the pandemic. In sensitivity analyses, the magnitude of the slope changes for weekly antipsychotic, antidepressant, trazodone, and benzodiazepine use were reduced but remained statistically significant in our models restricted to residents with dementia (eTable 5 in the Supplement).

    Discussion

    We found that the emergence of the COVID-19 pandemic was associated with statistically significant slope increases in the dispensation of antipsychotics, benzodiazepines, antidepressants (including trazodone), anticonvulsants, and opioids among residents of nursing homes in Ontario. In absolute terms, these increases were small compared with projected use (ie, approximately ≤1% for most classes, although slightly higher for antipsychotics and antidepressants). Interestingly, the slope increases and absolute differences in use observed for antipsychotics, antidepressants, and benzodiazepines were less pronounced when the analyses were restricted to residents with dementia. We did not observe any immediate level or slope changes of significance in the use of antibiotics, ARBs, or ACE inhibitors. COVID-19 has had a profound effect on the health of nursing home residents,7-10 staffing, and family caregiver availability.13-15 The consequences likely included a worsening of social isolation and loneliness45 and subsequent increased prevalence of depression and responsive behaviors among residents coupled with fewer available nonpharmacological options for their management. These adverse consequences may have contributed to increased prescribing of select medications among Ontario nursing home residents during the first wave of the pandemic.

    The absolute increases we observed for the psychotropic medications after the onset of the pandemic were similar to those reported by Stall et al.19 Both studies used the same administrative databases but different methodological approaches (eg, we used ARIMA models to estimate level and slope changes, assessed weekly medication patterns, and incorporated death data in deriving weekly denominators). The consistency of these findings enhances confidence in the nature and magnitude of the medication changes associated with the pandemic. Our sensitivity analyses further illustrate novel findings suggesting that slope increases and absolute differences in the use of psychotropics were smaller after the emergence of the first wave of the pandemic among residents with dementia. A UK study17 also showed a relatively lower (0.68%) absolute increase in the proportion of patients with dementia prescribed antipsychotics during the COVID-19 pandemic.

    Similar to our findings, claims data for all Ontario residents suggest that the use of antidepressants has increased slightly since the onset of the pandemic.46 Although this increased use is likely a marker of greater mental health distress, the use of antidepressants and other psychotropics may pose serious health risks to older nursing home residents (eg, increased confusion, sedation, and falls).22,47-49 It remains unknown what effect the increase in psychotropic medication use has had on resident-level outcomes. Additional research and continued monitoring are required to fully understand the persistence of these changes and their consequences for residents’ health and well-being.

    Data are notably scarce regarding the potential association of COVID-19 with opioid prescribing in nursing homes. In the community, the volume of weekly opioid prescriptions in Ontario decreased after the onset of the pandemic.46 In contrast, we observed a significant, albeit small, absolute increase in the proportion of nursing home residents who were dispensed an opioid during the same period. Our findings may reflect an increase in opioid use for end-of life care, pain management (eg, possibly from fall-related injuries because of diminished supervision), and/or the management of responsive behaviors among residents with dementia. The increases in benzodiazepine, opioid, and anticonvulsant use may point to a troubling rise in potentially inappropriate concurrent use of these medications during the early phase of the pandemic.23

    The COVID-19 pandemic has been identified as a potential threat to antimicrobial stewardship with subsequent risks for antibiotic overuse and greater antimicrobial resistance.50-52 A review of hospitalized patients with COVID-19 found bacterial coinfection to be relatively infrequent, suggesting most patients do not require antibiotics.53 Research indicates that antibiotic prescribing in UK general practices increased by an estimated 7% during the pandemic.54 Given the concerns associated with increased antimicrobial resistance among vulnerable older adults and risks for antibiotic-related adverse events among those living in nursing homes with high antibiotic use,55 it is reassuring that we found no change in antibiotic dispensations among residents after the onset of the COVID-19 pandemic.

    Early in the pandemic, various reports27-30 suggested that ARBs and ACE inhibitors might be associated with increased susceptibility to SARS-CoV-2 infection and worse outcomes for COVID-19 cases. Subsequent research31-34 has demonstrated that these agents do not augment COVID-19–related harms. The finding of no significant change in the dispensation of ARBs and ACE inhibitors after the pandemic among Ontario nursing home residents, despite these initial reports, is important given that the abrupt withdrawal of these medications can be harmful.29

    Implications

    During the past decade, various targeted strategies have successfully reduced the inappropriate use of antipsychotics, benzodiazepines, and opioids within nursing homes.20-23 Concerns have been raised that the COVID-19 pandemic might potentially reverse these successes because of serious disruptions in staffing, support, and services for residents. Our findings and those of Stall et al19 provide preliminary support for these concerns, although the absolute increases in psychotropic and other central nervous system medications during the first wave of the pandemic were small. Although a rise in short-term use of psychotropics may be appropriate because of a greater prevalence of accepted indications and diminished access to nonpharmacological options, studies in other populations56,57 show high rates of persistence in the use of these medications after initiation. Periodic medication reviews for residents should target psychotropics prescribed during the pandemic to minimize inappropriate persistence in their use.

    Strengths and Limitations

    Key strengths of our study include the use of population-based linked clinical and health administrative data (capturing residents of all Ontario nursing homes), robust analytical methods,41 and examination of medications commonly used and/or subject to quality monitoring in the nursing home setting. The major limitation of this work was that we were unable to directly correlate the observed medication changes with COVID-19 infection rates or deaths in these nursing homes. This will be an important area for future investigation. Other limitations include the use of dispensation dates (and days supplied) to identify medication use, which may not reflect whether a medication was taken as directed. Typically, this is not an important limitation, because medication use in Ontario nursing homes is closely supervised by clinicians. However, the effect of the pandemic on staff workload may have resulted in more missed doses for residents, particularly in homes with severe COVID-19 outbreaks. Our data do not allow us to comment on the relevant indications for treatment or its appropriateness at the individual level. Finally, our results provide a system-level overview of pandemic-related changes in medication prescribing across all nursing homes in Ontario and may not correspond to the trends experienced within individual nursing homes.

    Conclusions

    In this population-based cohort study of nursing home residents in Ontario, Canada, we observed statistically significant increases in the proportion of residents dispensed psychotropic, anticonvulsant, and opioid medications but no meaningful changes in the dispensation of antibiotics, ARBs, or ACE inhibitors during the first wave of the COVID-19 pandemic. Whether these medication trends continued during the second wave of the pandemic—which has arguably presented even greater challenges for staff, residents, and families—requires further study. The drivers and appropriateness of these medication changes, potential variation in prescribing behaviors across homes and clinical subpopulations, and any consequences for residents’ health and quality of life outcomes are all priority areas for future research. Targeted efforts are required to ensure that the increase in high-risk medications observed after the pandemic does not lead to inappropriate long-term use of these agents among residents.

    Back to top
    Article Information

    Accepted for Publication: May 21, 2021.

    Published: August 2, 2021. doi:10.1001/jamanetworkopen.2021.18441

    Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Campitelli MA et al. JAMA Network Open.

    Corresponding Author: Colleen J. Maxwell, PhD, School of Pharmacy, University of Waterloo, 200 University Ave West, Waterloo, ON N2L 3G1, Canada (colleen.maxwell@uwaterloo.ca).

    Author Contributions: Mr Campitelli had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

    Concept and design: Campitelli, Bronskill, Maclagan, Harris, Cotton, Tadrous, Gruneir, Maxwell.

    Acquisition, analysis, or interpretation of data: Campitelli, Bronskill, Cotton, Tadrous, Gruneir, Hogan, Maxwell.

    Drafting of the manuscript: Campitelli, Hogan, Maxwell.

    Critical revision of the manuscript for important intellectual content: Campitelli, Bronskill, Maclagan, Harris, Cotton, Tadrous, Gruneir, Maxwell.

    Statistical analysis: Campitelli, Maclagan, Harris, Cotton, Gruneir.

    Obtained funding: Bronskill, Maxwell.

    Administrative, technical, or material support: Harris.

    Supervision: Bronskill, Tadrous, Maxwell.

    Conflict of Interest Disclosures: Dr Bronskill reported receiving grants from the Canadian Institutes of Health Research (CIHR), nonfinancial support from ICES (formerly Institute for Clinical Evaluative Sciences), and grants from the Ontario Health Data Platform (OHDP) during the conduct of the study. Dr Tadrous reported receiving grants from the Ontario Ministry of Health (MOH) and the Ministry of Long-term Care (MLTC) during the conduct of the study. Dr Maxwell reported receiving grants from the CIHR, nonfinancial support from the ICES, and grants from the OHDP during the conduct of the study. No other disclosures were reported.

    Funding/Support: This research was funded by the CIHR through operating grant MOP-136854 (Exploring frailty and its role in the assessment of high-risk medications and risk of poor health outcomes in vulnerable populations), by ICES through an annual grant from the Ontario MOH and the MLTC; and by the OHDP, a Province of Ontario initiative to support Ontario’s ongoing response to COVID-19 and its related effects.

    Role of the Funder/Sponsor: The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

    Disclaimer: The opinions, results and conclusions reported in this article are those of the authors and are independent from the funding sources. No endorsement by the ICES, the MOH or MLTC, OHDP, its partners, or the Province of Ontario is intended or should be inferred. Parts of this material are based on data and information compiled and provided by the CIHI; however, the analyses, conclusions, opinions, and statements expressed herein are those of the authors and not necessarily those of CIHI.

    Additional Contributions: We thank IQVIA Solutions Canada Inc. for use of their Drug Information Database.

    Additional Information: The data set from this study is held securely in coded form at ICES. Although data sharing agreements prohibit ICES from making the data set publicly available, access may be granted to those who meet prespecified criteria for confidential access at https://www.ices.on.ca/DAS. Please contact the authors for any supplemental information related to the study such as the study protocol, analysis plan, or analytic code. The full data set creation plan and underlying analytic code are available from the authors upon request, understanding that the computer programs may rely on coding templates or macros that are unique to ICES and are therefore either inaccessible or may require modification.

    References
    1.
    Le Couteur  DG, Anderson  RM, Newman  AB.  COVID-19 through the lens of gerontology.   J Gerontol A Biol Sci Med Sci. 2020;75(9):e119-e120. doi:10.1093/gerona/glaa077 PubMedGoogle ScholarCrossref
    2.
    Montero-Odasso  M, Hogan  DB, Lam  R,  et al.  Age alone is not adequate to determine health-care resource allocation during the COVID-19 pandemic.   Can Geriatr J. 2020;23(1):152-154. doi:10.5770/cgj.23.452 PubMedGoogle ScholarCrossref
    3.
    White  EM, Santostefano  CM, Feifer  RA,  et al.  Asymptomatic and presymptomatic severe acute respiratory syndrome coronavirus 2 infection rates in a multistate sample of skilled nursing facilities.   JAMA Intern Med. 2020;180(12):1709-1711. doi:10.1001/jamainternmed.2020.5664 PubMedGoogle ScholarCrossref
    4.
    Arons  MM, Hatfield  KM, Reddy  SC,  et al; Public Health–Seattle and King County and CDC COVID-19 Investigation Team.  Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility.   N Engl J Med. 2020;382(22):2081-2090. doi:10.1056/NEJMoa2008457 PubMedGoogle ScholarCrossref
    5.
    Richardson  S, Hirsch  JS, Narasimhan  M,  et al; the Northwell COVID-19 Research Consortium.  Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area.   JAMA. 2020;323(20):2052-2059. doi:10.1001/jama.2020.6775 PubMedGoogle ScholarCrossref
    6.
    Myers  LC, Parodi  SM, Escobar  GJ, Liu  VX.  Characteristics of hospitalized adults with COVID-19 in an integrated health care system in California.   JAMA. 2020;323(21):2195-2198. doi:10.1001/jama.2020.7202 PubMedGoogle ScholarCrossref
    7.
    Comas-Herrera  A, Zalakaín  J, Lemmon  E,  et al. Mortality associated with COVID-19 in care homes: international evidence. Updated February 1, 2021. Accessed May 4, 2020. https://ltccovid.org/2020/04/12/mortality-associated-with-covid-19-outbreaks-in-care-homes-early-international-evidence/
    8.
    McMichael  TM, Currie  DW, Clark  S,  et al; Public Health–Seattle and King County, EvergreenHealth, and CDC COVID-19 Investigation Team.  Epidemiology of COVID-19 in a long-term care facility in King County, Washington.   N Engl J Med. 2020;382(21):2005-2011. doi:10.1056/NEJMoa2005412 PubMedGoogle ScholarCrossref
    9.
    Barnett  ML, Grabowski  DC.  Nursing homes are ground zero for COVID-19 pandemic.   JAMA Health Forum. 2020;1(3):e200369. doi:10.1001/jamahealthforum.2020.0369 Google Scholar
    10.
    Ouslander  JG, Grabowski  DC.  COVID-19 in nursing homes: calming the perfect storm.   J Am Geriatr Soc. 2020;68(10):2153-2162. doi:10.1111/jgs.16784 PubMedGoogle ScholarCrossref
    11.
    Van Houtven  CH, DePasquale  N, Coe  NB.  Essential long-term care workers commonly hold second jobs and double- or triple-duty caregiving roles.   J Am Geriatr Soc. 2020;68(8):1657-1660. doi:10.1111/jgs.16509 PubMedGoogle ScholarCrossref
    12.
    McGregor  MJ, Harrington  C.  COVID-19 and long-term care facilities: does ownership matter?   CMAJ. 2020;192(33):E961-E962. doi:10.1503/cmaj.201714 PubMedGoogle ScholarCrossref
    13.
    Xu  H, Intrator  O, Bowblis  JR.  Shortages of staff in nursing homes during the COVID-19 pandemic: what are the driving factors?   J Am Med Dir Assoc. 2020;21(10):1371-1377. doi:10.1016/j.jamda.2020.08.002 PubMedGoogle ScholarCrossref
    14.
    McGarry  BE, Grabowski  DC, Barnett  ML.  Severe staffing and personal protective equipment shortages faced by nursing homes during the COVID-19 pandemic.   Health Aff (Millwood). 2020;39(10):1812-1821. doi:10.1377/hlthaff.2020.01269 PubMedGoogle ScholarCrossref
    15.
    Verbeek  H, Gerritsen  DL, Backhaus  R, de Boer  BS, Koopmans  RTCM, Hamers  JPH.  Allowing visitors back in the nursing home during the COVID-19 crisis: a Dutch national study into first experiences and impact on well-being.   J Am Med Dir Assoc. 2020;21(7):900-904. doi:10.1016/j.jamda.2020.06.020 PubMedGoogle ScholarCrossref
    16.
    Ailabouni  NJ, Hilmer  SN, Kalisch  L, Braund  R, Reeve  E.  COVID-19 pandemic: considerations for safe medication use in older adults with multimorbidity and polypharmacy.   J Gerontol A Biol Sci Med Sci. 2021;76(6):1068-1073. doi:10.1093/gerona/glaa104 PubMedGoogle ScholarCrossref
    17.
    Howard  R, Burns  A, Schneider  L.  Antipsychotic prescribing to people with dementia during COVID-19.   Lancet Neurol. 2020;19(11):892. doi:10.1016/S1474-4422(20)30370-7 PubMedGoogle ScholarCrossref
    18.
    Leontjevas  R, Knippenberg  IAH, Smalbrugge  M,  et al.  Challenging behavior of nursing home residents during COVID-19 measures in the Netherlands.   Aging Ment Health. 2020;1-6. PubMedGoogle Scholar
    19.
    Stall  NM, Zipursky  JS, Rangrej  J,  et al.  Assessment of psychotropic drug prescribing among nursing home residents in Ontario, Canada, during the COVID-19 pandemic.   JAMA Intern Med. 2021;181(6):861-863. doi:10.1001/jamainternmed.2021.0224 PubMedGoogle ScholarCrossref
    20.
    Canadian Institute for Health Information [CIHI]. Drug use among seniors in Canada, 2016. Canadian Institute for Health Information; 2018. Accessed December 16, 2020. https://www.cihi.ca/sites/default/files/document/drug-use-among-seniors-2016-en-web.pdf
    21.
    Maclagan  LC, Maxwell  CJ, Gandhi  S,  et al.  Frailty and potentially inappropriate medication use at nursing home transition.   J Am Geriatr Soc. 2017;65(10):2205-2212. doi:10.1111/jgs.15016 PubMedGoogle ScholarCrossref
    22.
    Iaboni  A, Bronskill  SE, Reynolds  KB,  et al.  Changing pattern of sedative use in older adults: a population-based cohort study.   Drugs Aging. 2016;33(7):523-533. doi:10.1007/s40266-016-0380-3 PubMedGoogle ScholarCrossref
    23.
    Iaboni  A, Campitelli  MA, Bronskill  SE,  et al.  Time trends in opioid prescribing among Ontario long-term care residents: a repeated cross-sectional study.   CMAJ Open. 2019;7(3):E582-E589. doi:10.9778/cmajo.20190052 PubMedGoogle ScholarCrossref
    24.
    Daneman  N, Campitelli  MA, Giannakeas  V,  et al.  Influences on the start, selection and duration of treatment with antibiotics in long-term care facilities.   CMAJ. 2017;189(25):E851-E860. doi:10.1503/cmaj.161437 PubMedGoogle ScholarCrossref
    25.
    Maust  DT, Kim  HM, Chiang  C, Kales  HC.  Association of the Centers for Medicare & Medicaid Services’ national partnership to improve dementia care with the use of antipsychotics and other psychotropics in long-term care in the United States from 2009 to 2014.   JAMA Intern Med. 2018;178(5):640-647. doi:10.1001/jamainternmed.2018.0379 PubMedGoogle ScholarCrossref
    26.
    Zhao  D, Shridharmurthy  D, Alcusky  MJ,  et al.  The prevalence and factors associated with antiepileptic drug use in US nursing home residents.   Drugs Aging. 2020;37(2):137-145. doi:10.1007/s40266-019-00732-2 PubMedGoogle ScholarCrossref
    27.
    Cohen  JB, D’Agostino McGowan  L, Jensen  ET, Rigdon  J, South  AM.  Evaluating sources of bias in observational studies of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use during COVID-19: beyond confounding.   J Hypertens. 2021;39(4):795-805. doi:10.1097/HJH.0000000000002706PubMedGoogle ScholarCrossref
    28.
    Danser  AHJ, Epstein  M, Batlle  D.  Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers.   Hypertension. 2020;75(6):1382-1385. doi:10.1161/HYPERTENSIONAHA.120.15082 PubMedGoogle ScholarCrossref
    29.
    Vaduganathan  M, Vardeny  O, Michel  T, McMurray  JJV, Pfeffer  MA, Solomon  SD.  Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19.   N Engl J Med. 2020;382(17):1653-1659. doi:10.1056/NEJMsr2005760 PubMedGoogle ScholarCrossref
    30.
    Quinn  KL, Fralick  M, Zipursky  JS, Stall  NM.  Renin-angiotensin-aldosterone system inhibitors and COVID-19.   CMAJ. 2020;192(20):E553-E554. doi:10.1503/cmaj.200619 PubMedGoogle ScholarCrossref
    31.
    Hippisley-Cox  J, Young  D, Coupland  C,  et al.  Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people.   Heart. 2020;106(19):1503-1511. doi:10.1136/heartjnl-2020-317393 PubMedGoogle ScholarCrossref
    32.
    Fosbøl  EL, Butt  JH, Østergaard  L,  et al.  Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality.   JAMA. 2020;324(2):168-177. doi:10.1001/jama.2020.11301 PubMedGoogle ScholarCrossref
    33.
    Reynolds  HR, Adhikari  S, Pulgarin  C,  et al.  Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19.   N Engl J Med. 2020;382(25):2441-2448. doi:10.1056/NEJMoa2008975 PubMedGoogle ScholarCrossref
    34.
    World Health Organization. COVID-19 and the use of angiotensin-converting enzyme inhibitors and receptor blockers. May 7, 2020. Accessed December 22, 2020. https://www.who.int/news-room/commentaries/detail/covid-19-and-the-use-of-angiotensin-converting-enzyme-inhibitors-and-receptor-blockers
    35.
    Vaduganathan  M, van Meijgaard  J, Mehra  MR, Joseph  J, O’Donnell  CJ, Warraich  HJ.  Prescription fill patterns for commonly used drugs during the COVID-19 pandemic in the United States.   JAMA. 2020;323(24):2524-2526. doi:10.1001/jama.2020.9184 PubMedGoogle ScholarCrossref
    36.
    Government of Ontario. Personal Health Information Protection Act, 2004, S.O. 2004, Chapter. 3, Schedule. A. Updated June 3, 2021. Accessed June 25, 2021. https://www.ontario.ca/laws/statute/04p03
    37.
    Langan  SM, Schmidt  SA, Wing  K,  et al.  The Reporting of Studies Conducted Using Observational Routinely Collected Health Data Statement for Pharmacoepidemiology (RECORD-PE).   BMJ. 2018;363:k3532. doi:10.1136/bmj.k3532 PubMedGoogle Scholar
    38.
    Ng  R, Lane  N, Tanuseputro  P,  et al.  Increasing complexity of new nursing home residents in Ontario, Canada: a serial cross-sectional study.   J Am Geriatr Soc. 2020;68(6):1293-1300. doi:10.1111/jgs.16394 PubMedGoogle ScholarCrossref
    39.
    Campitelli  MA, Bronskill  SE, Hogan  DB,  et al.  The prevalence and health consequences of frailty in a population-based older home care cohort: a comparison of different measures.   BMC Geriatr. 2016;16:133. doi:10.1186/s12877-016-0309-z PubMedGoogle ScholarCrossref
    40.
    Austin  PC.  Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.   Stat Med. 2009;28(25):3083-3107. doi:10.1002/sim.3697 PubMedGoogle ScholarCrossref
    41.
    Bernal  JL, Cummins  S, Gasparrini  A.  Interrupted time series regression for the evaluation of public health interventions: a tutorial.   Int J Epidemiol. 2017;46(1):348-355.PubMedGoogle Scholar
    42.
    Public Health Ontario. Daily epidemiologic summary: COVID-19 in Ontario: January 15, 2020 to December 21, 2020. 2020. Accessed January 8, 2021. https://files.ontario.ca/moh-covid-19-report-en-2020-12-22.pdf
    43.
    Helfenstein  U.  The use of transfer function models, intervention analysis and related time series methods in epidemiology.   Int J Epidemiol. 1991;20(3):808-815. doi:10.1093/ije/20.3.808 PubMedGoogle ScholarCrossref
    44.
    Dickey  DA, Fuller  WA.  Distribution of the estimators for autoregressive time series with a unit root.   J Am Stat Assoc. 1979;74(366):427-431. doi:10.2307/2286348Google ScholarCrossref
    45.
    Abbasi  J.  Social isolation—the other COVID-19 threat in nursing homes.   JAMA. 2020;324(7):619-620. doi:10.1001/jama.2020.13484 PubMedGoogle ScholarCrossref
    46.
    Ontario Drug Policy Research Network. COVID-19 Ontario prescription drug utilization tool. Updated June 16, 2021. Accessed December 22, 2020. https://odprn.ca/covid19-ontario-prescription-drug-utilization-tool/
    47.
    Macri  JC, Iaboni  A, Kirkham  JG,  et al.  Association between antidepressants and fall-related injuries among long-term care residents.   Am J Geriatr Psychiatry. 2017;25(12):1326-1336. doi:10.1016/j.jagp.2017.08.014 PubMedGoogle ScholarCrossref
    48.
    Watt  JA, Gomes  T, Bronskill  SE,  et al.  Comparative risk of harm associated with trazodone or atypical antipsychotic use in older adults with dementia: a retrospective cohort study.   CMAJ. 2018;190(47):E1376-E1383. doi:10.1503/cmaj.180551 PubMedGoogle ScholarCrossref
    49.
    Bronskill  SE, Campitelli  MA, Iaboni  A,  et al.  Low-dose trazodone, benzodiazepines, and fall-related injuries in nursing homes: a matched-cohort study.   J Am Geriatr Soc. 2018;66(10):1963-1971. doi:10.1111/jgs.15519 PubMedGoogle ScholarCrossref
    50.
    Hsu  J.  How COVID-19 is accelerating the threat of antimicrobial resistance.   BMJ. 2020;369:m1983. doi:10.1136/bmj.m1983 PubMedGoogle Scholar
    51.
    Strathdee  SA, Davies  SC, Marcelin  JR.  Confronting antimicrobial resistance beyond the COVID-19 pandemic and the 2020 US election.   Lancet. 2020;396(10257):1050-1053. doi:10.1016/S0140-6736(20)32063-8 PubMedGoogle ScholarCrossref
    52.
    Arshad  M, Mahmood  SF, Khan  M, Hasan  R.  COVID-19, misinformation, and antimicrobial resistance.   BMJ. 2020;371:m4501. doi:10.1136/bmj.m4501 PubMedGoogle Scholar
    53.
    Langford  BJ, So  M, Raybardhan  S,  et al.  Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis.   Clin Microbiol Infect. 2020;26(12):1622-1629. doi:10.1016/j.cmi.2020.07.016 PubMedGoogle ScholarCrossref
    54.
    Armitage  R, Nellums  LB.  Antibiotic prescribing in general practice during COVID-19.   Lancet Infect Dis. 2021;21(6):e144. doi:10.1016/S1473-3099(20)30917-8PubMedGoogle Scholar
    55.
    Daneman  N, Bronskill  SE, Gruneir  A,  et al.  Variability in antibiotic use across nursing homes and the risk of antibiotic-related adverse outcomes for individual residents.   JAMA Intern Med. 2015;175(8):1331-1339. doi:10.1001/jamainternmed.2015.2770 PubMedGoogle ScholarCrossref
    56.
    Taipale  H, Särkilä  H, Tanskanen  A,  et al.  Incidence of and characteristics associated with long-term benzodiazepine use in Finland.   JAMA Netw Open. 2020;3(10):e2019029. doi:10.1001/jamanetworkopen.2020.19029 PubMedGoogle Scholar
    57.
    Lornstad  MT, Aarøen  M, Bergh  S, Benth  JS, Helvik  AS.  Prevalence and persistent use of psychotropic drugs in older adults receiving domiciliary care at baseline.   BMC Geriatr. 2019;19(1):119. doi:10.1186/s12877-019-1126-y PubMedGoogle ScholarCrossref
    ×